| Catalog No. | Size | Price (USD) |
| 12275-R072-1 | 1 mL | $1,969.87 |
| 12275-R072-20 | 20 µL | $118.49 |
| 12275-R072-50 | 50 µL | $177.58 |
| 12275-R072-100 | 100 µL | $340.51 |
General Information
| Product name | Recombinant Anti-CD82 Antibody, Rabbit Monoclonal |
| Validated applications | ELISA(Det) (FAQ Protocol) |
| Species reactivity | Reacts with: Human |
| Specificity | Human CD82 |
| Immunogen | Recombinant Human CD82 / KAI-1 Protein (Catalog#12275-H08H) |
| Preparation | This antibody was obtained from a rabbit immunized with purified, recombinant Human CD82 / KAI-1 (rh CD82 / KAI-1; Catalog#12275-H08H; P27701-1; Gly111-Leu228). |
| Source | Monoclonal Rabbit IgG Clone #072 |
| Purification | Protein A |
| Formulation | 0.2 μm filtered solution in PBS |
| Conjugate | Unconjugated |
| Form | Liquid |
| Shipping | This antibody is shipped as liquid solution at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Storage | This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free. Avoid repeated freeze-thaw cycles. |
Synonyms: Anti-4F9 Antibody; Anti-C33 Antibody; Anti-GR15 Antibody; Anti-IA4 Antibody; Anti-KAI1 Antibody; Anti-R2 Antibody; Anti-SAR2 Antibody; Anti-ST6 Antibody; Anti-TSPAN27 Antibody
Background Information
| Full Name | CD82 molecule |
| Description | CD82, also known as KAI-1, structurally belongs to tetraspanin family while categorised as metastasis suppressor gene on functional grounds. KAI1/CD82 is localized on cell membrane and form interactions with other tetraspanins, integrins and chemokines which are respectively responsible for cell migration, adhesion and signalling. Downregulation of CD82 expression is associated with the advanced stages of many human cancers and correlates with the acquisition of metastatic potential. Recent studies suggest that complex mechanisms underlie CD82 loss of function, including altered transcriptional regulation, splice variant production and post-translational protein modifications, and indicate a central role for CD82 in controlling metastasis as a 'molecular facilitator'. The loss of KAI1/CD82 expression in invasive and metastatic cancers is due to a complex, epigenetic mechanism that probably involves transcription factors such as NFkappaB, p53, and beta-catenin. A loss of KAI1 expression is also associated with the advanced stages of many human malignancies and results in the acquisition of invasive and metastatic capabilities by tumour cells. Thus, KAI1/CD82 is regarded as a wide-spectrum tumor metastasis suppressor. |
| References |
|
